Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results
FREMONT, Calif. , March 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2019, as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market
FREMONT, Calif. , March 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 11,903,506 shares
View HTML
Toggle Summary Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market
FREMONT, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the issuance and sale in a registered direct offering
View HTML
Toggle Summary Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine
FREMONT, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Qtrypta™ for filing and substantive review.
View HTML
Toggle Summary Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants
FREMONT, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN)  (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of (i) 10,146,154 Class A Units, each
View HTML
Toggle Summary Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
FREMONT, Calif. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock.
View HTML
Toggle Summary Zosano Announces FDA Submission of New Drug Application for Qtrypta
FREMONT, Calif. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the submission of a 505(b)(2) New Drug Application (“NDA”) for Qtrypta™ to the U.S. Food and Drug Administration (“FDA”) for the acute treatment
View HTML
Toggle Summary Zosano Announces Pricing of Registered Direct Offering
FREMONT, Calif. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate
View HTML
Toggle Summary Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 1:30 pm PT today FREMONT, Calif. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019 , as well as recent business
View HTML
Toggle Summary Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™
Zosano plans to submit NDA for Qtrypta in December 2019 FREMONT, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has received minutes from pre- New Drug Application (“NDA”) meetings with the Food
View HTML